Traveling Exhibit of Cancer Educational Material

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

MADISON, Wisconsin--The Am-erican Association for Cancer Education (AACE) and the European Association for Cancer Education have joined with the WHO International Network for Cancer Education (INCE) to put together a traveling exhibit of cancer educational materials for display at cancer congresses around the world.

MADISON, Wisconsin--The Am-erican Association for Cancer Education (AACE) and the European Association for Cancer Education have joined with the WHO International Network for Cancer Education (INCE) to put together a traveling exhibit of cancer educational materials for display at cancer congresses around the world.

The next major display of the exhibit will be at the 17th International Cancer Congress in Rio de Janeiro, August 23-28, 1998. The NCI in Rio has agreed to accept educational materials prior to the meeting and hold them for the INCE to transfer to the exhibit site.

Educational materials suitable for such an exhibit can be sent to: Evaldo Abren, M.D.-Coordinator Pro-Onco; Av. Venezuela, 134, bloco A; 20081-370 Rio de Janeiro-RJ; Brasil.

Articles in this issue
Calling the National Cancer Institute
Six Cycles of AT Found Safe in Advanced Breast Cancer
New Drug Promising in Advanced Pancreatic Cancer
Herceptin/Chemo Effective in Metastatic Breast Cancer
Virtual Reality Exhibit Simulates Cancer Fatigue
New Director of AIDS Research
Exhibit Explores Healing Power of Creating Artwork
Update on Trials of Thrombopoietin for Platelet Recovery
Amifostine Reduces Xerostomia After RT for Head and Neck Cancer
National Survey Documents Gap in Quality of HIV/AIDS Care
Taxotere Improves Survival More than MV in Anthracycline-Resistant Breast Cancer
Stomach Cancer Susceptibility Gene Found in the Maori
Study Shows 6-Month Chemo Regimen Should Be New Colon Cancer Standard
Nurses Urged to Be Alert for Depression in Cancer Patients
Androgen Ablation Added to RT Improves Outcome in Locally Advanced Prostate Cancer
Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Related Content
Findings from the phase 3 CARTITUDE-4 trial support the European approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

European Commission Approves Cilta-cel in R/R Multiple Myeloma

April 24th 2024
Article

Findings from the phase 3 CARTITUDE-4 trial support the European approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers | Image Credit: © freshidea - stock.adobe.com.

Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers

April 24th 2024
Article

The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

FDA Approves Tovorafenib for Relapsed/Refractory Low-Grade Glioma

April 23rd 2024
Article

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.

Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC

April 23rd 2024
Article

Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.